PTJ
BSTC

Paul Tudor Jones’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Paul Tudor Jones’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,234
Closed -$202K – 1440
2019
Q1 		$202K Sell
3,234
-456
-12% -$30.2K 0.01% 1001
2018
Q4 		$224K Buy
+3,690
New +$220K ﹤0.01% 845

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's BSTC Position: Q2 2019 in Review

Paul Tudor Jones sold out of BioSpecifics Technologies Corp. (BSTC) in Q2 2019, closing a stake of 3,234 shares — an estimated $202K sold.

Paul Tudor Jones first reported a position in BSTC in Q4 2018 and held it in 2 quarters. The position peaked at $224K in Q4 2018. 114 funds tracked by Wall St. Rank hold BSTC as of Q2 2019.

  • Paul Tudor Jones reported no remaining BioSpecifics Technologies Corp. position as of Q2 2019 after selling out during the quarter.
  • Paul Tudor Jones sold 3,234 BioSpecifics Technologies Corp. shares in Q2 2019, an estimated $202K.
  • Paul Tudor Jones first reported a position in BioSpecifics Technologies Corp. in Q4 2018 and held it in 2 quarters.
  • Paul Tudor Jones's BioSpecifics Technologies Corp. position peaked at $224K in Q4 2018.
  • 114 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q2 2019.

Based on Tudor Investment Corp's 13F filing for Q2 2019, filed 14 Aug 2019.